GenioDx will have the exclusive right to market, sell and distribute Anteo's range of Anteobind products in China, specifically within the Chinese in-vitro diagnostics (IVD) market and
targeting market leading Chinese manufacturers of point of care (POC) and diagnostics products according to Anteo.
They have agreed to conduct a comprehensive promotional campaign targeting prospective Chinese customers with the purpose of gathering market based feedback to further refine the value proposition of Anteo's products.
After a mutually - agreed initial review, GenioDx will then undertake a full - scale countrywide product launch to prospective customers with the aim of capturing early evaluators of Anteo's products and to establish a business plan for next year.
Use of the words promotional, targeting, prospective customers IMO indicates that there is a hell of a lot of work to be done yet.
Even if they do establish a decent sizable customer base, refine the value proposition of Anteo's products and establish a business plan accordingly it will be at least 12 to 18 months before any significant revenue rolls into the Anteo coffers.
It is speculative and subject to a lot of variables whether Anteo and GenioDx will even arrive at a mutually agreeable deal at the conclusion of their respective due diligence.
